Quantcast

Latest Vascular endothelial growth factor Stories

2014-10-17 08:25:24

TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA(®) (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both...

2014-10-14 16:28:33

WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house developed agent lenvatinib mesylate (lenvatinib) as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) and granted the NDA Priority Review status. Priority Review designation occurs when the FDA believes the drug has the...

2014-10-08 08:26:24

-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since its launch in Canada in 2007, Lucentis(®) has treated more than 100,000 eyes across all approved indications(3 ) DORVAL, QC, Oct. 8, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc. announced today that Lucentis(®) (ranibizumab), the treatment for several major causes of vision loss, has been...

2014-10-06 16:27:54

EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct. 6, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition...

painkiller
2014-10-03 03:00:37

Emma Thorne, The University of Nottingham A major medical discovery by scientists at The University of Nottingham could lead to the development of an entirely new type of painkiller. A drug resulting from the research, published in the journal Neurobiology of Disease, would offer new hope to sufferers of chronic pain conditions such as traumatic nerve injury, for which few effective painkillers are currently available. The work, led by Dr. Lucy Donaldson in the University’s School...

2014-09-29 08:30:12

A single ILUVIEN implant provides treatment for three years ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will hold a conference call to provide additional information regarding the recent approval by the U.S. Food and Drug Administration (FDA) of ILUVIEN(®) for the treatment of...

2014-09-22 04:21:43

TARRYTOWN, N.Y., Sept. 22, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA(®) (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). EYLEA has already been approved in Japan for the treatment of patients with neovascular age-related macular degeneration (wet AMD), and...

2014-09-18 12:29:19

Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that Regeneron's Eylea, the most recently launched anti-vascular endothelial growth factor (VEGF) agent for wet AMD, is equally likely to be covered on commercial and Medicare Advantage plans as Genentech's Lucentis, which is the standard of care...

2014-09-18 08:26:01

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA(TM)) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in the online version of The Lancet Oncology. In the trial, known as RAINBOW, the addition of ramucirumab to...

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related